Alnylam to Webcast TTR Investor Webinar

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

03/10/2026 - 08:00 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.

The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA^® in ATTR-CM, will highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company’s flagship TTR franchise.

The webinar will feature Alnylam’s senior commercial and medical leaders, including:

Tolga Tanguler – Chief Commercial Officer
John Kennedy – SVP, TTR Franchise Global Commercialization Lead
Mark Soued – SVP, Head of U.S. & TTR Lead
Sameer Bansilal – VP, Medical Affairs, TTR Disease Area Lead

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.